Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology
Tal Nuriel, Sergio L Angulo, Usman Khan, Archana Ashok, Qiuying Chen, Helen Y Figueroa, Sheina Emrani, Li Liu, Mathieu Herman, Geoffrey Barrett, Valerie Savage, Luna Buitrago, Efrain Cepeda-Prado, Christine Fung, Eliana Goldberg, Steven S Gross, S Abid Hussaini, Herman Moreno, Scott A Small, Karen E Duff, Tal Nuriel, Sergio L Angulo, Usman Khan, Archana Ashok, Qiuying Chen, Helen Y Figueroa, Sheina Emrani, Li Liu, Mathieu Herman, Geoffrey Barrett, Valerie Savage, Luna Buitrago, Efrain Cepeda-Prado, Christine Fung, Eliana Goldberg, Steven S Gross, S Abid Hussaini, Herman Moreno, Scott A Small, Karen E Duff
Abstract
The ε4 allele of apolipoprotein E (APOE) is the dominant genetic risk factor for late-onset Alzheimer's disease (AD). However, the reason APOE4 is associated with increased AD risk remains a source of debate. Neuronal hyperactivity is an early phenotype in both AD mouse models and in human AD, which may play a direct role in the pathogenesis of the disease. Here, we have identified an APOE4-associated hyperactivity phenotype in the brains of aged APOE mice using four complimentary techniques-fMRI, in vitro electrophysiology, in vivo electrophysiology, and metabolomics-with the most prominent hyperactivity occurring in the entorhinal cortex. Further analysis revealed that this neuronal hyperactivity is driven by decreased background inhibition caused by reduced responsiveness of excitatory neurons to GABAergic inhibitory inputs. Given the observations of neuronal hyperactivity in prodromal AD, we propose that this APOE4-driven hyperactivity may be a causative factor driving increased risk of AD among APOE4 carriers.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
References
- Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–1356. doi: 10.1001/jama.1997.03550160069041.
- Mahley RW, Rall SC., Jr. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000;1:507–537. doi: 10.1146/annurev.genom.1.1.507.
- Han X. The role of apolipoprotein E in lipid metabolism in the central nervous system. Cell Mol. Life Sci. 2004;61:1896–1906. doi: 10.1007/s00018-004-4009-z.
- Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006312.
- Bales KR, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997;17:263–264. doi: 10.1038/ng1197-263.
- Castano EM, et al. Fibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 1995;306(Pt 2):599–604. doi: 10.1042/bj3060599.
- Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron. 1993;11:575–580. doi: 10.1016/0896-6273(93)90070-8.
- Schmechel DE, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA. 1993;90:9649–9653. doi: 10.1073/pnas.90.20.9649.
- Ma J, et al. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92–94. doi: 10.1038/372092a0.
- Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 2011;3:89ra57. doi: 10.1126/scitranslmed.3002156.
- Holtzman DM, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA. 2000;97:2892–2897. doi: 10.1073/pnas.050004797.
- Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. Trends Mol. Med. 2010;16:287–294. doi: 10.1016/j.molmed.2010.04.004.
- Wolf AB, et al. Apolipoprotein E as a beta-amyloid-independent factor in alzheimer’s disease. Alzheimers Res. Ther. 2013;5:38. doi: 10.1186/alzrt204.
- Busche MA, et al. Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in Alzheimer’s models. Nat. Neurosci. 2015;18:1725–7. doi: 10.1038/nn.4163.
- Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science. 2008;321:1686–1689. doi: 10.1126/science.1162844.
- Davis KE, Fox S, Gigg J. Increased hippocampal excitability in the 3xTgAD mouse model for Alzheimer’s disease in vivo. PLoS ONE. 2014;9:e91203. doi: 10.1371/journal.pone.0091203.
- Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007;55:697–711. doi: 10.1016/j.neuron.2007.07.025.
- Hamalainen A, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol. Aging. 2007;28:1889–1903. doi: 10.1016/j.neurobiolaging.2006.08.008.
- Kircher TT, et al. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J. Neurol. Neurosurg. Psychiatry. 2007;78:812–818. doi: 10.1136/jnnp.2006.104877.
- Bakker A, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467–474. doi: 10.1016/j.neuron.2012.03.023.
- Dickerson BC, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404–411. doi: 10.1212/01.wnl.0000171450.97464.49.
- Miller SL, et al. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J. Neurol. Neurosurg. Psychiatry. 2008;79:630–635. doi: 10.1136/jnnp.2007.124149.
- Quiroz YT, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer’s disease. Ann. Neurol. 2010;68:865–875. doi: 10.1002/ana.22105.
- Sepulveda-Falla D, Glatzel M, Lopera F. Phenotypic profile of early-onset familial Alzheimer’s disease caused by presenilin-1 E280A mutation. J. Alzheimers Dis. 2012;32:1–12.
- Das U, et al. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79:447–460. doi: 10.1016/j.neuron.2013.05.035.
- Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913–922. doi: 10.1016/j.neuron.2005.10.028.
- Yamamoto K, et al. Chronic optogenetic activation augments abeta pathology in a mouse model of Alzheimer disease. Cell Rep. 2015;11:859–865. doi: 10.1016/j.celrep.2015.04.017.
- Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389–394. doi: 10.1038/embor.2013.15.
- Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 2014;211:387–393. doi: 10.1084/jem.20131685.
- Wu JW, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 2016;19:1085–92. doi: 10.1038/nn.4328.
- Filippini N, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl Acad. Sci. USA. 2009;106:7209–7214. doi: 10.1073/pnas.0811879106.
- Bookheimer SY, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N. Engl. J. Med. 2000;343:450–456. doi: 10.1056/NEJM200008173430701.
- Trachtenberg AJ, Filippini N, Mackay CE. The effects of APOE-epsilon4 on the BOLD response. Neurobiol. Aging. 2012;33:323–334. doi: 10.1016/j.neurobiolaging.2010.03.009.
- Fleisher AS, et al. Cerebral perfusion and oxygenation differences in Alzheimer’s disease risk. Neurobiol. Aging. 2009;30:1737–1748. doi: 10.1016/j.neurobiolaging.2008.01.012.
- Wierenga CE, et al. Effect of mild cognitive impairment and APOE genotype on resting cerebral blood flow and its association with cognition. J. Cereb. Blood Flow Metab. 2012;32:1589–1599. doi: 10.1038/jcbfm.2012.58.
- Jack CR, Jr, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216. doi: 10.1016/S1474-4422(12)70291-0.
- Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 1997;272:17972–17980. doi: 10.1074/jbc.272.29.17972.
- Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience. 2004;124:725–733. doi: 10.1016/j.neuroscience.2003.10.011.
- Moreno H, Hua F, Brown T, Small SA. Longitudinal mapping of mouse cerebral blood volume with MRI. NMR in Biomedicine. 2006;19:535–543. doi: 10.1002/nbm.1022.
- Moreno H, et al. Imaging the abeta-related neurotoxicity of Alzheimer disease. Arch. Neurol. 2007;64:1467–1477. doi: 10.1001/archneur.64.10.1467.
- Raichle ME. Positron emission tomography. Annu. Rev. Neurosci. 1983;6:249–267. doi: 10.1146/annurev.ne.06.030183.001341.
- Leenders KL, et al. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain. 1990;113:27–47. doi: 10.1093/brain/113.1.27.
- Gonzalez RG, et al. Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. Am. J. Neuroradiol. 1995;16:1763–1770.
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta. Neuropathol. 1991;82:239–259. doi: 10.1007/BF00308809.
- Richards K, et al. Segmentation of the mouse hippocampal formation in magnetic resonance images. Neuroimage. 2011;58:732–740. doi: 10.1016/j.neuroimage.2011.06.025.
- Hussaini SA, Kempadoo KA, Thuault SJ, Siegelbaum SA, Kandel ER. Increased size and stability of CA1 and CA3 place fields in HCN1 knockout mice. Neuron. 2011;72:643–653. doi: 10.1016/j.neuron.2011.09.007.
- Kohara K, et al. Cell type-specific genetic and optogenetic tools reveal hippocampal CA2 circuits. Nat. Neurosci. 2014;17:269–279. doi: 10.1038/nn.3614.
- Quirk MC, Sosulski DL, Feierstein CE, Uchida N, Mainen ZF. A defined network of fast-spiking interneurons in orbitofrontal cortex: responses to behavioral contingencies and ketamine administration. Front. Syst. Neurosci. 2009;3:13. doi: 10.3389/neuro.06.013.2009.
- Chen Q, et al. Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice. PLoS ONE. 2012;7:e37149. doi: 10.1371/journal.pone.0037149.
- Wang X, Michaelis ML, Michaelis EK. Functional genomics of brain aging and Alzheimer’s disease: focus on selective neuronal vulnerability. Curr. Genomics. 2010;11:618–633. doi: 10.2174/138920210793360943.
- Minoshima S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann. Neurol. 1997;42:85–94. doi: 10.1002/ana.410420114.
- Cepeda-Prado E, et al. R6/2 Huntington’s disease mice develop early and progressive abnormal brain metabolism and seizures. J. Neurosci. 2012;32:6456–6467. doi: 10.1523/JNEUROSCI.0388-12.2012.
- Walther H, Lambert JD, Jones RS, Heinemann U, Hamon B. Epileptiform activity in combined slices of the hippocampus, subiculum and entorhinal cortex during perfusion with low magnesium medium. Neurosci. Lett. 1986;69:156–161. doi: 10.1016/0304-3940(86)90595-1.
- Kunitake A, Kunitake T, Stewart M. Differential modulation by carbachol of four separate excitatory afferent systems to the rat subiculum in vitro. Hippocampus. 2004;14:986–999. doi: 10.1002/hipo.20016.
- Criscuolo C, et al. BDNF prevents amyloid-dependent impairment of LTP in the entorhinal cortex by attenuating p38 MAPK phosphorylation. Neurobiol. Aging. 2015;36:1303–1309. doi: 10.1016/j.neurobiolaging.2014.11.016.
- Canto CB, Witter MP. Cellular properties of principal neurons in the rat entorhinal cortex. I. The lateral entorhinal cortex. Hippocampus. 2012;22:1256–1276. doi: 10.1002/hipo.20997.
- Alonso A, Klink R. Differential electroresponsiveness of stellate and pyramidal-like cells of medial entorhinal cortex layer II. J. Neurophysiol. 1993;70:128–143.
- Prange O, Murphy TH. Correlation of miniature synaptic activity and evoked release probability in cultures of cortical neurons. J. Neurosci. 1999;19:6427–6438.
- Liraz O, Boehm-Cagan A, Michaelson DM. ApoE4 induces Abeta42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol. Neurodegener. 2013;8:16. doi: 10.1186/1750-1326-8-16.
- Sullivan PM, Mace BE, Estrada JC, Schmechel DE, Alberts MJ. Human apolipoprotein E4 targeted replacement mice show increased prevalence of intracerebral hemorrhage associated with vascular amyloid deposition. J. Stroke Cerebrovasc. Dis. 2008;17:303–311. doi: 10.1016/j.jstrokecerebrovasdis.2008.03.011.
- Klein RC, Acheson SK, Mace BE, Sullivan PM, Moore SD. Altered neurotransmission in the lateral amygdala in aged human apoE4 targeted replacement mice. Neurobiol. Aging. 2014;35:2046–2052. doi: 10.1016/j.neurobiolaging.2014.02.019.
- Hunter JM, et al. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Res. 2012;1467:120–132. doi: 10.1016/j.brainres.2012.05.048.
- Gillespie AK, et al. Apolipoprotein E4 causes age-dependent disruption of slow gamma Oscillations during Hippocampal sharp-wave ripples. Neuron. 2016;90:740–751. doi: 10.1016/j.neuron.2016.04.009.
- Sullivan D, et al. Relationships between hippocampal sharp waves, ripples, and fast gamma oscillation: influence of dentate and entorhinal cortical activity. J. Neurosci. 2011;31:8605–8616. doi: 10.1523/JNEUROSCI.0294-11.2011.
- Haier RJ, et al. Temporal cortex hypermetabolism in down syndrome prior to the onset of dementia. Neurology. 2003;61:1673–1679. doi: 10.1212/01.WNL.0000098935.36984.25.
- Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease. Ann. Neurol. 1999;45:466–472. doi: 10.1002/1531-8249(199904)45:4<466::AID-ANA8>;2-Q.
- Small SA, Tsai WY, DeLaPaz R, Mayeux R, Stern Y. Imaging hippocampal function across the human life span: is memory decline normal or not? Ann. Neurol. 2002;51:290–295. doi: 10.1002/ana.10105.
- de Leon MJ, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc. Natl Acad. Sci. USA. 2001;98:10966–10971. doi: 10.1073/pnas.191044198.
- Karow DS, et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology. 2010;256:932–942. doi: 10.1148/radiol.10091402.
- Khan UA, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer’s disease. Nat. Neurosci. 2014;17:304–311. doi: 10.1038/nn.3606.
- Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–539. doi: 10.1038/416535a.
- Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837–842. doi: 10.1038/nm1782.
- Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925–937. doi: 10.1016/S0896-6273(03)00124-7.
- Gomez-Isla T, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J. Neurosci. 1996;16:4491–4500.
- Hoover BR, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067–1081. doi: 10.1016/j.neuron.2010.11.030.
- Brickman AM, Small SA, Fleisher A. Pinpointing synaptic loss caused by Alzheimer’s disease with fMRI. Behav. Neurol. 2009;21:93–100. doi: 10.1155/2009/246892.
- Sabuncu MR, Yeo BT, Van Leemput K, Vercauteren T, Golland P. Asymmetric image-template registration. Med. Image Comput. Comput. Assist. Interv. 2009;12:565–573.
- Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 2008;49:1137–1146. doi: 10.1194/jlr.D700041-JLR200.
- Giavalisco P, et al. Elemental formula annotation of polar and lipophilic metabolites using (13) C, (15) N and (34) S isotope labelling, in combination with high-resolution mass spectrometry. Plant J. 2011;68:364–376. doi: 10.1111/j.1365-313X.2011.04682.x.
- Woodhall GL, Bailey SJ, Thompson SE, Evans DI, Jones RS. Fundamental differences in spontaneous synaptic inhibition between deep and superficial layers of the rat entorhinal cortex. Hippocampus. 2005;15:232–245. doi: 10.1002/hipo.20047.
- von Kienlin M, et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 2005;18:32–39. doi: 10.1016/j.nbd.2004.09.005.
- Salek RM, et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer’s disease. Neurochem. Int. 2010;56:937–947. doi: 10.1016/j.neuint.2010.04.001.
Source: PubMed